Six University Spinoffs to Watch in H2 2026 File IPO Prospectuses

University Spinoffs, also known as university startups or spin-off companies, refer to emerging enterprises incubated by universities or research centers. These companies are typically founded by faculty members, researchers, or students who leverage intellectual property, research findings, or technologies developed within the university to create commercial products or services. Such companies play a crucial role in translating academic research into tangible products, stimulating economic growth, fostering collaboration, and addressing societal challenges. They bridge the gap between academia and industry, drive innovation, and generate benefits for both universities and society at large.

The following companies, all spun out from universities, have experienced rapid growth in recent years, achieving breakthrough results in their respective frontier fields and translating them into product prototypes with long-term market value.

Company: Colorifix

University: University of Cambridge

Direction: Dyeing of Synthetic Bio-fabrics

Colorifix, a biotechnology company incubated by the University of Cambridge, aims to address the harmful chemicals involved in petrochemical dye production and the industry’s annual consumption of five trillion liters of water.

With the ultimate goal of replacing synthetic dyes, the company engineers microorganisms to produce natural dyes. Engineers identify colors derived from plants, insects, or microorganisms and use DNA sequencing to discover the genes responsible for pigment production. They then employ genetic engineering to modify microorganisms, enabling them to produce specific pigments.

This biotechnology company also supplies its genetically engineered microorganisms to other companies for pigment production via fermentation. This process is highly analogous to beer brewing, wherein the microorganisms proliferate rapidly with the aid of a nutrient medium, yielding colored dyes within a few days. These dyes are then utilized in dyeing machines to color various types of fabrics, eliminating the need for toxic chemicals.

Colorifix, headquartered in the UK, has entered into an in-depth collaboration with the Swedish multinational fashion brand H&M to further develop its products. Reportedly, Colorifix’s technology platform not only reduces water and chemical usage by 77% and 80%, respectively, but also significantly mitigates ozone layer depletion.

The company was founded in 2016 and has raised a total of $31.8 million across three rounds of financing, with the latest $22.7 million Series B round led by H&M Group’s venture capital arm. As the incubator, Cambridge Enterprise has continued to provide follow-on investment.

Company: Complement Therapeutics

University: The University of Manchester

Direction: Innovative Therapies for AMD

Complement Therapeutics is a UK-based company dedicated to treating age-related macular degeneration (AMD) by targeting the complement system. As a common degenerative retinal disease, AMD is the leading cause of blindness among individuals aged 65 and older. It is categorized into dry AMD, which accounts for 80–90% of cases and progresses slowly, and wet AMD, which is less prevalent but characterized by a more rapid progression and greater severity of damage.

The complement system is a cascade of plasma proteins that defends against infection by inducing inflammatory responses. However, dysregulation of these pathways can lead to diseases such as age-related macular degeneration (AMD) and hematologic disorders. The startup is currently focusing on its lead candidate, CTx001, an AAV gene therapy for advanced AMD, which is in the preclinical stage. Clinical trials for CTx001 are scheduled to begin in 2024. Complement Therapeutics is also concurrently developing CTx002, CTx003, and CTx004 for the treatment of complement-mediated kidney diseases, factor H-related protein (FHR) dysregulation, and complement-mediated neuroinflammation.

In addition, the company’s Complement Precision Medicine (CPM) platform can measure more than 30 complement proteins from blood samples.

Earlier this year, the company secured €72 million ($78.5 million) in a Series A financing round. Participants in this round included Forbion, BGV, Panakes Partners, and Cambridge Innovation Capital (CIC), among others. Spun out of the University of Manchester, the company received its initial funding from BioGeneration Ventures (BGV) in 2021.

Company: Delix Therapeutics

University: UC Davis

Direction: Innovative Therapies for Mental and Brain Disorders

In neuropsychiatric disorders, neurons in certain brain regions gradually degenerate and lose synapses, leading to symptoms such as cognitive impairment and emotional dysregulation. With over one billion people worldwide affected by neuropsychiatric conditions, there is an urgent unmet clinical need for novel therapeutic approaches. In this context, Delix Therapeutics has identified a class of drugs known as psychoplastogens for the treatment of depression and other related disorders.

Neuroplasticity enables the regrowth of atrophied neurons and the restoration of neural circuits in the brain. First- and second-generation drugs, such as ketamine and psilocybin, are hallucinogens that may cause adverse reactions and cardiovascular issues; however, the company is striving to develop third-generation agents. These new drugs will be non-hallucinogenic and offer an improved safety profile.

The lead candidate in the company’s pipeline is DLX-001, a therapeutic agent for treatment-resistant major depressive disorder, currently undergoing Phase I clinical trials. This candidate also holds significant importance for academic research in psychiatry, as 80% of patients failed to achieve symptom relief with existing treatments.

Delix Therapeutics, founded in 2019 and headquartered in Boston, Massachusetts, was co-founded by UC Davis Professor David Olson. The company has raised a total of $118 million across five rounds of financing, with its most recent round completed in 2022 and including Comerica, an investment firm focused on the life sciences sector.

Company: Epic Bio

University: Stanford University

Direction: Epigenetic Editing

U.S.-based Epic Bio focuses on the field of epigenetics. Spun out of Stanford University in 2018, the company was founded by Professor Lei Qi, a renowned bioengineering expert and co-inventor of CRISPR patents held by the University of California. The company has developed a platform technology called the Gene Expression Modulation System (GEMS) for the treatment of various diseases.

When the epigenome (which controls how DNA is read) malfunctions, gene expression may become aberrant, leading to disease. The GEMS platform comprises a non-cleaving CRISPR-Cas variant capable of identifying genes and regulators of gene expression, with the aim of correcting the manner in which genes are read. The company leverages genetic engineering to optimize DNA-binding proteins. Furthermore, its CasMINI is the smallest Cas protein synthesized to date. Through this technology, Epic aims to address challenges associated with delivery and safety risks arising from epigenetic regulation of gene expression during CRISPR-Cas9 gene editing.

The company is developing five drug candidates through its GEMS platform. The most advanced candidate in its pipeline is EPI-321, indicated for the treatment of facioscapulohumeral muscular dystrophy (FSHD). EPI-321 is designed to suppress the expression of the DUX4 gene, as overexpression of this gene is the primary cause of FSHD. Following favorable pharmacokinetic and safety results for EPI-321, Epic plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) later this year.

The company raised $55 million in its Series A financing round last year, with investors including Horizon Ventures, which is backed by Li Ka-shing.

Company: KinSea Lead Discovery AS

Universities: UiT The Arctic University of Norway, University of Bergen, Norinnova, and Lead Discovery Center GmbH

Direction: Innovative Cancer Therapies

KinSea Lead Discovery AS is a biotechnology company co-incubated by multiple universities and research institutions, established in September 2022. The startup focuses on developing bioactive compounds derived from marine organisms for the treatment of specific types of cancer.

As marine organisms are rich in bioactive compounds with nutritional properties and health-promoting effects, the company has developed a method to extract and utilize these compounds from Arctic Ocean seawater for the treatment of acute myeloid leukemia (AML) and hematologic malignancies. Although the company’s pipeline has not been publicly disclosed, its lead candidate is a targeted therapy based on FLT3 inhibition. FLT3 inhibitors are multi-kinase inhibitors that kill cancer cells by binding to mutated FLT3 proteins and blocking their activity. The company has successfully completed animal proof-of-concept studies and plans to proceed with further preclinical trials.

KinSea Lead Discovery AS, headquartered in Tromsø, Norway, secured seed funding this year from KHAN Technology Transfer Fund I (KHAN-I), an early-stage life sciences venture capital firm based in Germany. Previously, the company had received grants from the Research Council of Norway and MABIT, a regional biotechnology program.

Company: Morphoceuticals

University: Tufts University

Direction: Regenerative Medicine

Morphoceuticals, hailing from Tufts University in Massachusetts, USA, has achieved major breakthroughs in the field of regenerative medicine, particularly in limb regeneration.

University researchers successfully regenerated frog legs by performing RNA sequencing on early tissue buds of the African clawed frog (Xenopus laevis). The study found that combination therapy with multiple drugs could induce the regrowth of hind limbs in frogs. The amputated limbs were covered with silicone caps containing anti-inflammatory agents and collagen synthesis inhibitors to prevent scar tissue formation, which can impede normal tissue development. This biotechnology company successfully regenerated nearly fully functional legs, excluding the toe webbing. Although the company has not yet conducted human trials, this research offers hope to millions of patients who have undergone amputation due to trauma, diabetes, and other causes.

Morphoceuticals was founded three years ago and raised $8 million in its seed funding round this January. Investors participating in the financing included the UK-based biotechnology company Juvenescence and early-stage investor Prime Movers Lab.